[go: up one dir, main page]

BRPI0514666A - antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes - Google Patents

antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes

Info

Publication number
BRPI0514666A
BRPI0514666A BRPI0514666-6A BRPI0514666A BRPI0514666A BR PI0514666 A BRPI0514666 A BR PI0514666A BR PI0514666 A BRPI0514666 A BR PI0514666A BR PI0514666 A BRPI0514666 A BR PI0514666A
Authority
BR
Brazil
Prior art keywords
combination
pdes
inhibitors
receptor antagonists
phosphodiestrase
Prior art date
Application number
BRPI0514666-6A
Other languages
English (en)
Inventor
Donald Jeffrey Keyser
Richard Dixon
Original Assignee
Encysive Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals filed Critical Encysive Pharmaceuticals
Publication of BRPI0514666A publication Critical patent/BRPI0514666A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ANTAGONISTAS DE RECEPTOR DE ENDOTELINA A (ET~ A~) EM COMBINAçãO COM INIBIDORES DE FOSFODIESTERASE 5 (PDES) E USOS DESTES A presente invenção refere-se em geral às terapias de combinação compreendendo um antagonista de receptor de endotelina A (ET~ A~) e um inibidor de fosfodiesterase 5 (PDE5), composições farmacêuticas compreendendo o antagonista de ET~ A~ e inibidor de PDE5 e métodos de tratar vários distúrbios compreendendo administrar um antagonista de ET~ A~ e um inibidor de PDE5. Em particular, as terapias de combinação e composições farmacêuticas são úteis para o tratamento e/ou prevenção de distúrbios cardíacos como hipertensão arterial pulmonar (PAH).
BRPI0514666-6A 2004-08-26 2005-08-26 antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes BRPI0514666A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60446204P 2004-08-26 2004-08-26
US11/211,099 US20060205733A1 (en) 2004-08-26 2005-08-25 Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
PCT/US2005/030342 WO2006026395A1 (en) 2004-08-26 2005-08-26 Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0514666A true BRPI0514666A (pt) 2008-06-17

Family

ID=36000390

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514666-6A BRPI0514666A (pt) 2004-08-26 2005-08-26 antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes

Country Status (12)

Country Link
US (1) US20060205733A1 (pt)
EP (1) EP1789051A4 (pt)
JP (1) JP2008510830A (pt)
KR (1) KR20070074552A (pt)
AU (1) AU2005280077A1 (pt)
BR (1) BRPI0514666A (pt)
CA (1) CA2578044A1 (pt)
IL (1) IL181513A0 (pt)
MX (1) MX2007002311A (pt)
NO (1) NO20071446L (pt)
RU (1) RU2007110933A (pt)
WO (1) WO2006026395A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG169238A1 (en) 2004-08-11 2011-03-30 Williamsburg Holdings Llc Noncardiotoxic pharmaceutical compounds
CA2587499A1 (en) * 2004-11-18 2006-05-26 Schering Corporation Methods of using pde v inhibitors for the treatment of congestive heart failure
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
US20070031349A1 (en) * 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
CA2644784A1 (en) * 2006-03-13 2007-09-20 Jinling Chen Formulations of sitaxsentan sodium
KR20080104149A (ko) * 2006-03-13 2008-12-01 엔싸이시브 파마슈티칼즈 인코퍼레이티드 확장기 심장 부전의 치료를 위한 방법 및 조성물
US20090104265A1 (en) * 2006-03-13 2009-04-23 John Reichwein Polymorphs of N-(4-chloro-3-methyl-5-isoxazolyl) 2-[2-methyl-4,5-(methylenedioxy)phenylacetyl] thiophene-3-sulfonamide, sodium salt
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
WO2007146900A2 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
AU2007333115B2 (en) 2006-12-12 2013-01-10 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN103432133B (zh) 2007-01-22 2016-08-10 Gtx公司 核受体结合剂的用途
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US20090004268A1 (en) * 2007-03-13 2009-01-01 Given Bruce D Methods and Compositions for Treatment of an Interstitial Lung Disease
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
AU2013203192B2 (en) * 2007-06-11 2015-12-24 Edge Therapeutics Inc. A drug delivery system for the prevention of cerebral vasospasm
CA2690600C (en) * 2007-06-11 2016-10-11 R. Loch Macdonald A drug delivery system for the prevention of cerebral vasospasm
EP2187928A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of anti-inflammatory peptide 1 as a therapeutic agent
CN101891747B (zh) * 2010-07-02 2012-04-25 张南 抑制5型磷酸二酯酶的化合物及制备方法
HUE033346T2 (en) * 2010-10-15 2017-11-28 Gilead Sciences Inc Compositions and methods for treating pulmonary hypertension
EP2694133B1 (en) 2011-04-05 2018-05-23 Edge Therapeutics, Inc. Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
JP6144631B2 (ja) * 2012-01-31 2017-06-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シタキセンタン誘導体
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
WO2014138738A1 (en) * 2013-03-08 2014-09-12 Abbive Inc. Methods of treating acute kidney injury
JP2020500183A (ja) * 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
KR102896033B1 (ko) * 2022-12-22 2025-12-04 연세대학교 산학협력단 N-벤질퀴나졸린-4-아민 화합물을 포함하는, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
MXPA00003997A (es) * 1999-04-30 2002-03-08 Lilly Icos Llc Articulos de fabricacion.
WO2002062343A2 (en) * 2001-02-02 2002-08-15 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination

Also Published As

Publication number Publication date
MX2007002311A (es) 2008-03-10
EP1789051A4 (en) 2009-10-21
IL181513A0 (en) 2007-07-04
WO2006026395A1 (en) 2006-03-09
NO20071446L (no) 2007-03-26
JP2008510830A (ja) 2008-04-10
KR20070074552A (ko) 2007-07-12
US20060205733A1 (en) 2006-09-14
RU2007110933A (ru) 2008-10-10
EP1789051A1 (en) 2007-05-30
CA2578044A1 (en) 2006-03-09
AU2005280077A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
BRPI0514666A (pt) antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes
CY1121338T1 (el) Χρηση αλατων του αναστολεα kinασης janus (r)-3-(4-(7h-πυρρολο[2,3-d]πυριμιδιν-4-υλο)-1η-πυραζολ-1-υλο)-3-κυκλοπεντυλο- προπανονιτριλιο
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
BR112013008140A2 (pt) "compostos imidazotriazinona".
BRPI0518281A2 (pt) inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
NO20071048L (no) Amidoforbindelser og deres anvendelse som farmasoytika
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
BRPI0512630A (pt) compostos de amido e seu uso como produtos farmacêuticos
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
BRPI0518105A (pt) uso de antagonista da angiogênese e uso de anticorpo anti-vegf
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
DK1711185T3 (da) Kombination af roscovitin-CS-682 eller dens metabolit CNDAC
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.